WallStreetZenWallStreetZen

NASDAQ: IBIO
Ibio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IBIO

Based on 2 analysts offering 12 month price targets for Ibio Inc

Min Forecast
$5.00+502.41%
Avg Forecast
$5.50+562.65%
Max Forecast
$6.00+622.89%

Should I buy or sell IBIO stock?

Based on 2 analysts offering ratings for Ibio Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IBIO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IBIO as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their IBIO stock forecasts and price targets.

IBIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-06
lockedlocked$00.00+00.00%2024-12-17

1 of 1

Forecast return on equity

Is IBIO forecast to generate an efficient return?

Company
-196.68%
Industry
1,433.89%
Market
73.38%
IBIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IBIO forecast to generate an efficient return on assets?

Company
-117.17%
Industry
1,033.93%
IBIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IBIO earnings per share forecast

What is IBIO's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.73
Avg 2 year Forecast
-$1.36

IBIO revenue forecast

What is IBIO's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$200.0k-46.67%
IBIO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IBIO revenue growth forecast

How is IBIO forecast to perform vs Biotechnology companies and vs the US market?

Company
-46.67%
Industry
3,102.65%
Market
53.24%
IBIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IBIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IBIO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IBIO$0.83$5.50+562.65%Strong Buy
MRKR$1.28$10.25+700.78%Strong Buy
BRTX$1.82N/AN/A
SYBX$1.18N/AN/A
MEIP$2.08N/AN/A
View Top Biotech Stocks

Ibio Stock Forecast FAQ

Is Ibio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: IBIO) stock is to Strong Buy IBIO stock.

Out of 2 analysts, 2 (100%) are recommending IBIO as a Strong Buy, 0 (0%) are recommending IBIO as a Buy, 0 (0%) are recommending IBIO as a Hold, 0 (0%) are recommending IBIO as a Sell, and 0 (0%) are recommending IBIO as a Strong Sell.

If you're new to stock investing, here's how to buy Ibio stock.

What is IBIO's earnings growth forecast for 2025-2026?

(NASDAQ: IBIO) Ibio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.21%.

Ibio's earnings in 2025 is -$20,992,000.On average, 2 Wall Street analysts forecast IBIO's earnings for 2025 to be -$28,495,760, with the lowest IBIO earnings forecast at -$28,743,549, and the highest IBIO earnings forecast at -$28,247,971.

In 2026, IBIO is forecast to generate -$22,383,626 in earnings, with the lowest earnings forecast at -$33,864,526 and the highest earnings forecast at -$10,902,725.

What is IBIO's revenue growth forecast for 2025-2025?

(NASDAQ: IBIO) Ibio's forecast annual revenue growth rate of -46.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 3,102.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 53.24%.

Ibio's revenue in 2025 is $375,000.

In 2025, IBIO is forecast to generate $3,303,856 in revenue, with the lowest revenue forecast at $3,303,856 and the highest revenue forecast at $3,303,856.

What is IBIO's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: IBIO) forecast ROA is -117.17%, which is lower than the forecast US Biotechnology industry average of 1,033.93%.

What is IBIO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year IBIO price target, the average IBIO price target is $5.50, with the highest IBIO stock price forecast at $6.00 and the lowest IBIO stock price forecast at $5.00.

On average, Wall Street analysts predict that Ibio's share price could reach $5.50 by May 6, 2026. The average Ibio stock price prediction forecasts a potential upside of 562.65% from the current IBIO share price of $0.83.

What is IBIO's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: IBIO) Ibio's current Earnings Per Share (EPS) is -$0.31. On average, analysts forecast that IBIO's EPS will be -$1.73 for 2025, with the lowest EPS forecast at -$1.74, and the highest EPS forecast at -$1.71. In 2026, IBIO's EPS is forecast to hit -$1.36 (min: -$2.05, max: -$0.66).

What is IBIO's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: IBIO) forecast ROE is -196.68%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.